newsfilter
← Latest News
Business Wire·

Enveric Biosciences Reports New Preclinical Data Supporting the Non-Hallucinogenic Profile of Lead Candidate EB-003

GloSensor™ assay findings align with previously reported BRET assay data as EB-003 advances toward planned Phase 1 clinical development Enveric Biosciences (NASDAQ:ENVB) ("Enveric" or the "Company"),